American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

ISS Staging May Be Inadequate in Classifying All Patients with Newly Diagnosed MM by Disease and Symptom Burden

This study analyzed data from the longitudinal CoMMpass trial led by the Multiple Myeloma Research Foundation to determine the degree to which the International Staging System (ISS) stage was associated with disease and symptom burden in patients with newly diagnosed multiple myeloma (MM). Read More ›

Bortezomib-Based Induction and Maintenance Therapy Results in Durable Survival Improvements in Newly Diagnosed MM Patients

Researchers reported long-term follow-up results of the HOVON-65/GMMG-HD4 trial that evaluated survival outcomes with bortezomib-based induction and maintenance regimens followed by high-dose melphalan and autologous stem-cell transplantation in transplant-eligible patients with newly diagnosed multiple myeloma (MM) compared with the standard regimen. The impact of the bortezomib-based regimen on survival in the high-risk cytogenetic and renally impaired subset of patients was also reported. Read More ›

Clinical Benefit of Bortezomib/Melphalan/Prednisone Followed by Lenalidomide/Dexamethasone in Elderly Newly Diagnosed Patients with MM

To further optimize therapy, this study identified subgroups that benefited least from bortezomib/melphalan/prednisone followed by lenalidomide/dexamethasone regimen in newly diagnosed patients aged 65 to 80 years with multiple myeloma (MM) included in the GEM2010 trial. Read More ›

Getting to Adherence‑Based Monitoring

Ali McBride provides some ideas to promoting oral adherence. Read More ›

Getting Better Medication Adherence for Oral Oncolytics

R. Donald Harvey offers suggestions for what might help with greater medication adherence. Read More ›

Helping to Relieve Patients' Financial Burden

Ali McBride offers suggestions and ways to help patients with out-of-pocket expenses. Read More ›

Understanding the Medication Puzzle

Beth Faiman talks about the excitement of new medications but the challenge of getting to a standard of care that includes these new drugs. Read More ›

Assessing the Best Treatment Path for Patients

Beth Faiman talks about the excitement of new medications but the challenge of getting to a standard of care that includes these new drugs. Read More ›

Getting to a Multiple Myeloma Standard of Care

Beth Faiman talks about the excitement of new medications but the challenge of getting to a standard of care that includes these new drugs. Read More ›

Evaluation of Geriatric Assessment Tools in Elderly Patients with MM

Researchers reported results of a real-world prospective study that evaluated different geriatric assessment tools and comorbidity indices as well as standard disease-related prognostic factors in consecutive unselected patients aged >65 years with symptomatic multiple myeloma (MM). Read More ›

American Society of Hematology (ASH)

Page 5 of 44